Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-877 (Pemafibrate) and Cyclosporine DDI Study
NCT02276001Phase 1Completed
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemafibrate in dyslipidemia (2 arms). Primary endpoint: Maximum concentration at 72 hours. Started Jun 2014; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02276001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276001.